The biotech’s efforts to bring its vaccines to the country mean navigating political pushback in the U.S. and the risk of ...
Norovirus, often erroneously called the "stomach flu," sickens an estimated 21 million Americans and 685 million people ...
Health on MSN16h
How Much Longer Do We Have to Wait for a Norovirus Vaccine?Despite millions of cases of norovirus in the U.S. each year—and a current surge in outbreaks—there is still no vaccine for ...
In absolute dollar amount, the Cambridge drugmaker had the biggest drop in market cap among any public Massachusetts company ...
With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO ...
In a report released on January 7, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...
The Covid-19 positivity rate has also seen a rise to 7.1% this past week, versus the 5.5% figure for the past four weeks.
The number of layoffs in the U.S. pharmaceutical industry exceeded 14,000 last year, a 9% increase from 2023 ...
Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.
Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.
Stocktwits on MSN1d
Moderna Stock Tumbles After Best Day In 7 Months, But Retail Confidence Holds FirmShares of Moderna Inc. fell over 8% on Wednesday afternoon, paring some of the gains from Tuesday, the stock’s best trading ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback